# CVS HEALTH CORPORATION (CVS) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/CVS Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Sep 6, 2026 CVS HEALTH CORPORATION (CVS) last closed at $96.74, in the upper half of its 52-week range of $69.51–$110.68. Composite market sentiment across 1 analysis is positive (+26 on a −100 to +100 scale), as of Sep 6, 2026. ## What the data says At $96.74, the stock sits roughly midway to the upper end of a 52-week band that runs from $69.51 to $110.68 — a spread of about 59% from low to high, which is a wide track for a company of this size and points to a year in which sentiment moved considerably rather than settling into a narrow range. The current price is close to 13% below the high and about 39% above the low. The market is valuing the business at roughly $124 billion, or about 25.5 times trailing earnings against 11.4 times forward earnings — a gap that reflects expectations of materially higher earnings ahead rather than the recent past. Price to book sits at 1.55. The profitability picture behind that is thin: a net margin near 1.2%, which is characteristic of a business that moves enormous revenue at very small take rates, alongside revenue growth of about 7.1%. The shares yield roughly 2.75%, and a beta of 0.58 indicates the price has historically moved less than the broad market. Recent coverage has been a mix of company-specific and sector-level items. The company-focused pieces track its post-earnings share move, an improving balance sheet in the context of deleveraging, and a rally on September 1. The rest place it in a wider frame — comparisons against UNH and AbbVie, a piece on healthcare providers as an ETF exposure, a look at potential beneficiaries of GLP-1 demand, and a dividend-oriented article — so a fair share of the news flow is about where the company sits within healthcare rather than about the company alone. ## About CVS HEALTH CORPORATION CVS Health Corporation is a health care company operating across insurance, pharmacy services, and retail. Its Health Care Benefits segment, which includes Aetna, offers medical, pharmacy, dental, and behavioral health coverage along with Medicare Advantage, Medicare Supplement, and standalone prescription drug plans, and it administers Medicaid managed care programs. Members reach these plans through employers, government programs, public insurance exchanges, unions, and individual enrollment. The Health Services segment provides pharmacy benefit management through Caremark, covering plan design and administration, formulary and retail network management, specialty and mail-order dispensing, and clinical and medical-spend management for employers, insurers, health plans, and government sponsors. The Pharmacy & Consumer Wellness segment operates the company's retail drugstores and online pharmacy, filling prescriptions and selling over-the-counter medicines, health and beauty items, and general merchandise, and it supplies drugs and pharmacy consulting to long-term care and other care settings, including infusion and enteral nutrition services. Founded in 1963 and formerly named CVS Caremark Corporation, the company took its current name in 2014 and is headquartered in Woonsocket, Rhode Island. ## Company profile - Symbol: CVS - Exchange: NYSE - Security type: Stock - Sector: Healthcare - Industry: Healthcare Plans - Composite sentiment: positive (26 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $123.73B | | Enterprise value | $186.27B | | Trailing P/E | 25.53 | | Forward P/E | 11.36 | | Price to book | 1.55 | | Price to sales | 0.3 | | Dividend yield | 2.75% | | Beta | 0.58 | | Net margin | 1.18% | | Revenue growth | 7.10% | | Earnings growth | 1.89% | | 52-week high | $110.68 | | 52-week low | $69.51 | | Average volume | 7.82M | ## Related stocks - [CI](https://synoptiv.com/stock/CI) - [LH](https://synoptiv.com/stock/LH) - [DGX](https://synoptiv.com/stock/DGX) - [GH](https://synoptiv.com/stock/GH) - [LH](https://synoptiv.com/stock/LH) - [BTSG](https://synoptiv.com/stock/BTSG) - [DVA](https://synoptiv.com/stock/DVA) - [HNGE](https://synoptiv.com/stock/HNGE) - [CHE](https://synoptiv.com/stock/CHE) - [HIMS](https://synoptiv.com/stock/HIMS) ## Recent news - [CVS Health (CVS) Makes Updated 2026 2027 COVID 19 Vaccines Available Nationwide](https://finance.yahoo.com/healthcare/articles/cvs-health-cvs-makes-updated-170533423.html) — Sep 5, 2026 - [Jim Cramer Says “Own It, Don’t Trade It” as CVS Health Gains Momentum](https://finance.yahoo.com/markets/stocks/articles/jim-cramer-says-own-don-103206104.html) — Sep 5, 2026 - [CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?](https://www.zacks.com/stock/news/2985233/cvs-health-cvs-up-1-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2985233) — Sep 4, 2026 - [Is CVS Health Outperforming the Nasdaq?](https://www.barchart.com/story/news/4442639/is-cvs-health-outperforming-the-nasdaq) — Sep 4, 2026 - [1 Healthcare Stock for Long-Term Investors and 2 We Ignore](https://finance.yahoo.com/healthcare/articles/1-healthcare-stock-long-term-100610856.html) — Sep 4, 2026 - [Living With Primary Immunodeficiency: How Specialty Care Supports Nick's Journey](/news/389074/living-with-primary-immunodeficiency-how-specialty-care-supports-nicks-journey) — Sep 4, 2026 - [Life Insurance Premium Growth Fuels Q2 Gains For U.S. Life Insurers](https://seekingalpha.com/article/4943040-life-insurance-premium-growth-fuels-q2-gains-for-us-life-insurers) — Sep 4, 2026 - [UnitedHealth Stock Recovered Before Its Margins Did](https://www.trefis.com/articles/614234/unitedhealth-stock-recovered-before-its-margins-did/2026-09-03) — Sep 3, 2026 - [CVS Stock Has Left Its Peers Behind. Or Has It?](https://www.trefis.com/articles/614065/cvs-stock-has-left-its-peers-behind-or-has-it/2026-09-03) — Sep 3, 2026 - [Updated COVID-19 vaccines available at CVS Pharmacy and MinuteClinic across the U.S.](/news/388804/updated-covid-19-vaccines-available-at-cvs-pharmacy-and-minuteclinic-across-the-us) — Sep 3, 2026 ## Frequently asked questions ### What is the current market sentiment for CVS? As of Sep 6, 2026, CVS HEALTH CORPORATION (CVS) carries positive (+26 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has CVS stock been performing? CVS HEALTH CORPORATION last closed at $96.74, in the upper half of its 52-week range of $69.51–$110.68. ### What is CVS's market cap and valuation? CVS HEALTH CORPORATION has a market capitalization of about $123.73B, a trailing P/E of 25.5, a dividend yield of 2.75%. ### What sector is CVS in, and who are its competitors? CVS HEALTH CORPORATION operates in the Healthcare sector, specifically Healthcare Plans. Comparable companies include CI, LH, DGX, GH, LH. ### Where can I find a full analysis of CVS? The full CVS report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/CVS/v/1) (account and access required)